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Abstract 
Background: Bipolar spectrum disorders are frequently under-recognized and/or 
misdiagnosed in various settings. Several influential publications recommend the routine 
screening of bipolar disorder. A systematic review and meta-analysis of accuracy studies for 
the bipolar spectrum diagnostic scale (BSDS), the hypomania checklist (HCL-32) and the 
mood disorder questionnaire (MDQ) was performed.  
Methods: The Pubmed, EMBASE, Cochrane, PsycINFO and SCOPUS databases were 
searched. Studies were included if the accuracy properties of the screening measures were 
determined against a DSM or ICD-10 structured diagnostic interview. The QUADAS-2 tool 
was used to rate bias.  
Results: 53 original studies met inclusion criteria (N=21,542). At recommended cutoffs, 
summary sensitivities were 81.%, 66% and 69%, while specificities were 67%, 79% and 
86% for the HCL-32, MDQ, and BSDS in psychiatric services, respectively. The HCL-32 
was more accurate than the MDQ for the detection of type II bipolar disorder in mental 
health care centers (P=0.018). At a cutoff of 7, the MDQ had a summary sensitivity of 43% 
and a summary specificity of 95% for detection of bipolar disorder in primary care or 
general population settings.  
Limitations: Most studies were performed in mental health care settings. Several included 
studies had a high risk of bias. 
Conclusions: Although accuracy properties of the three screening instruments did not 
consistently differ in mental health care services, the HCL-32 was more accurate than the 
MDQ for the detection of type II BD. More studies in other settings (for example, in primary 
care) are necessary. 
Keywords: Bipolar disorder; screening; accuracy studies; systematic review; meta-analysis 
Highlights  
Bipolar spectrum disorders are under-recognized in various settings. 
Influential publications recommend the routine screening of bipolar disorder. 
An accuracy meta-analysis of the HCL-32, MDQ and BSDS was performed. 
The accuracies for the HCL-32, MDQ and BSDS did not differ in psychiatric services. 
The HCL-32 was more accurate than the MDQ for the detection of type II BD. 
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1. Introduction 
The diagnosis of bipolar disorders in most circumstances is not straightforward and requires 
a careful assessment of its longitudinal course. Almost three thirds of individuals with 
bipolar disorders report having received a misdiagnosis at least once, while a proper 
diagnosis takes on average ten years from the initiation of affective symptoms (Drancourt et 
al., 2013; Lish et al., 1994). Evidences also indicate that bipolar disorder is prevalent and 
frequently under-recognized in primary care (Cerimele et al., 2014; Culpepper, 2014). 
Furthermore, depressive symptoms and episodes more frequently predominate in the 
longitudinal course of bipolar disorders (Judd et al., 2003); this results in a significant 
proportion of individuals with BD being misdiagnosed as having unipolar depression 
(Hirschfeld and Vornik, 2004). These patients misdiagnosed as having major depressive 
disorder are more likely to receive antidepressant monotherapy (Matza et al., 2005) which 
may result in manic switches, cycle acceleration, and possibly heightened suicidality (Bond 
et al., 2008; Ghaemi et al., 2004; Undurraga et al., 2012). 
 The use of self-report screening instruments for bipolar disorder that are both time- 
and cost-effective may aid in the timely recognition of this illness. In the last several years 
four self-report questionnaires have been developed to screen for bipolar spectrum disorders, 
namely the mood disorders questionnaire (MDQ) (Hirschfeld et al., 2000), the bipolar 
spectrum diagnostic scale (BSDS) (Ghaemi et al., 2005), the hypomanic checklist (HCL-32) 
(Angst et al., 2005) and the mood swings questionnaire/survey (MSQ/MSS) (Parker et al., 
2008; Parker et al., 2006). These screening tools are readily available for clinical use. 
Briefly, the MDQ screens for a lifetime history of (hypo) mania with 13 yes/no questions 
reflecting DSM-IV criteria. These questions are followed by a single yes/no question asking 
whether the symptoms clustered in the same period. The final question evaluates the level of 
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impairment resulting from the symptoms. The MDQ developers recommended a cut-off 
score of seven endorsed symptoms that co-occurred and caused at least moderate 
impairment.(Hirschfeld et al., 2000) The BSDS consists of two parts. The first part is a 
paragraph containing 19 statements describing several manifestations of bipolar disorder. 
Each affirmatively checked sentence is counted as 1 point. The second part of the BSDS is a 
single multiple-choice question asking respondents how well the paragraph describes their 
behavior (very well or almost perfect-6 points; fairly well- 4 points; to some degree but not 
in most respects-2 points; not really at all-0 points). In the initial study, a cut-off point of 13 
yielded the best balance of sensitivity/specificity (Ghaemi et al., 2005). In the HCL-32, after 
a brief introduction, the respondent is instructed to think of a period when he/she was in a 
“high” state and answer 32 yes/no questions about their mood and behavior during that 
period. Each ‘yes’ response is scored 1, whereas each ‘no’ answer is scored as 0. In the 
initial study, the authors suggested a cut-off score of 14 (Angst et al., 2005). 
Notwithstanding several influential publications recommend the routine screening in 
clinical practice (Anderson et al., 2012; Chessick and Dimidjian, 2010; Frye, 2011; 
Loganathan et al., 2010), concerns have been raised regarding the validity and applicability 
of these screening tools (Phelps and Ghaemi, 2006; Zimmerman, 2012; Zimmerman et al., 
2010). Phelps and Ghaemi used previously published data on sensitivity and specificity of 
the MDQ and BSDS to estimate positive and negative predictive values at varying 
prevalence levels using Bayesian statistical concepts (Phelps and Ghaemi, 2006). At lower 
prevalence or low prior clinical probability (for example, in primary care), high negative 
predictive values were verified indicating that both instruments effectively rule out bipolar 
disorders. However, in these contexts the positive predictive value significantly dropped 
resulting in a higher number of ‘false positives’. 
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 The BSDS, HCL-32 and MDQ have been the most extensively investigated 
screening tools for bipolar spectrum disorders in accuracy studies and epidemiological 
surveys. Therefore, the overarching aims of this report were to perform a systematic review 
and meta-analysis to evaluate and compare the diagnostic accuracy of these three screening 
tools in different clinical settings. Our secondary objective was to investigate the effect of 
pre-defined potential sources of heterogeneity on estimates of test performance.         
2. Method 
2.1.  Search Strategy and selection of studies 
 Studies were identified through three methods. First, we conducted comprehensive 
computerized literature searches in five bibliographical databases – MEDLINE, EMBASE, 
Cochrane CENTRAL, PsycInfo and SCOPUS – from inception to January 9th, 2014. Search 
strings are provided in the supplementary material S1 that accompanies the online edition of 
this article.  Second, this search strategy was augmented through tracking citations of 
included articles in Google Scholar. Finally, references of relevant reviews were examined 
to identify potentially relevant studies (see references in the Supplementary Material). No 
language restrictions were applied. This review followed the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement (Liberati et al., 2009) and the 
Cochrane Handbook for Diagnostic Test Accuracy Reviews (Macaskill, 2010). Two 
investigators screened title/abstracts for potential eligibility. Disagreements were resolved 
through consensus. References selected for full-text review were evaluated by two 
independent raters. Disagreements were resolved by discussion. 
 We included studies in which the diagnostic accuracy of the MDQ, the BSDS or the 
HCL-32 was investigated in general adult psychiatric populations, primary care or in 
community-derived samples with validated structured psychiatric interviews for the DSM-
IV or DSM-IV-TR as reference standards. Studies were excluded if they: involved 
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perinatal/postpartum specific populations; involved child and adolescent samples; did not 
use a validated structured interview as reference standard; did not provide data for deriving a 
two-by-two table (FP- false positives; FN- false negatives; TN- true negatives and TP- true 
positives) even after corresponding authors were contacted for additional data.  
2.2.  Data extraction and quality assessment 
 Using a structured spreadsheet, data on the following characteristics were extracted: 
author, publication year, study design, setting, sample size, reference standard, version of the 
screening instrument and data for two-by-two tables. We appraised the quality of included 
studies by using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) 
tool.(Whiting et al., 2011). Briefly, the QUADAS-2 tool consists of four domains: patient 
selection, index test, reference standard, and flow and timing. The four domains are assessed 
for risk of bias and the first three domains are also assessed for concerns regarding 
applicability. We developed guidance tailored to this review on how to appraise and 
interpret each signaling question within the domains. Two authors (JKS and THF) extracted 
data and assessed each included study according to the QUADAS-2 criteria. Inter-rater 
agreement of the QUADAS-2 assessment was excellent (overall Kappa value=0.81). 
Disagreements were resolved through consensus. 
2.3.  Meta-analyses 
 To explore variation in diagnostic accuracy between studies, we plotted estimates of 
the observed sensitivities and specificities for each test in forest plots and in receiver-
operating characteristic (ROC) space using data for a single cut-off from each study. Each 
summary ROC (SROC) curve shows the expected trade-off between sensitivity and 
specificity across studies using different cut-off scores for each instrument. Sensitivity refers 
to a test’s ability to correctly identify individuals with a given disorder, and is computed as 
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the number of individuals with the disorder that were classified as test positives (i.e. TP) 
divided by the total number of individuals with the disorder. Specificity refers to a test’s 
ability to identify those without the disorder, and is computed as the number of individuals 
without the disorder who were classified as test negatives (i.e. TN) divided by the total 
number of individuals without the disorder. We analyzed data from studies conducted in 
different clinical settings separately (categorized as mental health care settings and primary 
care/general population settings). We considered bipolar disorder in general and then 
performed separate analyses for bipolar disorder type II and bipolar disorder not otherwise 
specified (NOS) where data were available.  
 Since studies used different cut-offs to define a positive screen for each test, 
whenever sufficient data were available we performed meta-analyses using hierarchical 
summary ROC (HSROC) models. The HSROC model includes random effects parameters 
that allow for variation in accuracy and cut-off between studies. The model also includes a 
shape parameter that allows accuracy to vary with cut-off thus enabling asymmetry in the 
shape of the SROC curve. If a study reported sensitivity and specificity at multiple cut-offs, 
the optimum cut-off (as defined by the authors based on the most adequate balance between 
sensitivity and specificity) was selected. Thus, only a pair of sensitivity and specificity from 
each study was included in a meta-analysis. To enable estimation of the average operating 
point (summary sensitivity and specificity) for each test at a specific cut-off, we restricted 
meta-analysis to studies that reported the cut-off. Whenever few studies were available, we 
simplified the HSROC model by assuming a symmetrical SROC curve or fixed effects for 
the accuracy and/or threshold parameters. 
 We compared the diagnostic accuracy of the three instruments obtained from all 
included studies (indirect comparison), and then performed additional analyses restricted to 
studies that made head-to-head comparisons (i.e. applied two of the instruments to the same 
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participants). We made test comparisons by adding a covariate for test type to the HSROC 
model to assess the effect of test type on the accuracy, cut-off and/or shape parameters of the 
model. Since summary sensitivities and specificities are only clinically interpretable when 
the studies included in a meta-analysis use a common cut-off, we estimated sensitivity at 
points on the SROC curves corresponding to the lower quartile, median and upper quartile 
of the specificities observed in the studies included in the meta-analysis. In addition, 
whenever the estimated SROC curves had the same shape, we calculated the relative 
diagnostic odds ratio (RDOR) as a summary of the relative accuracy of two screening 
instruments. To assess the statistical significance of differences in test accuracy, likelihood 
ratio tests were used for comparisons of models with and without covariate terms.  
 To investigate heterogeneity in the diagnostic accuracy of each instrument, we added 
potential sources of heterogeneity as a covariate to the HSROC model (meta-regression). We 
a priori considered the following variables: language of the instrument (Asian vs. non-
Asian); two signaling questions from the patient selection domain of the QUADAS-2 tool 
that reflect patient recruitment (‘Was a consecutive or random sample of patients enrolled?’) 
and study design (‘Was a case control design avoided?’). Finally, the percentage of bipolar 
disorder type II/NOS in each included study (categorized as either < or ≥ median values of 
included studies) was also investigated as a potential source of heterogeneity in test 
performance for detection of bipolar disorder in general.  
All HSROC analyses were performed using the NLMIXED procedure in the SAS 
software (version 9.2; SAS Institute, Cary, North Carolina) (Macaskill, 2004). We used 
Review Manager (version 5.2; Copenhagen; The Nordic Cochrane Center, The Cochrane 
Collaboration, 2012) to generate forest plots and SROC plots. Significance level was set at 
α=0.05. 
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3. Results 
3.1. Selection of studies 
 Figure 1 summarizes the study selection process. After examining a total of 541 titles 
and abstracts (371 after removal of duplicates), we selected 84 unique references for further 
consideration. We excluded 31 of the retrieved articles (reasons for exclusion are provided 
in Supplementary Table S1). A total of 53 original studies (5,566 bipolar disorder cases; 
21,543 patients) met our inclusion criteria. Descriptive characteristics of the included studies 
are provided in Supplementary Table S2.  
<Insert Fig.1. around here> 
3.2. Assessment of bias of included studies 
 Supplementary Table S3 shows the overall risk of bias and applicability concerns for 
the 53 included studies. A large proportion of studies (19 studies; 35.8%) showed a high risk 
of bias in the ‘patient selection domain’ and also gave high applicability concern in the same 
domain; 11 of the studies used a case-control design and did not enroll a consecutive sample 
of patients. Overall, most studies had a high risk of bias in at least one QUADAS-2 domain 
(29 studies; 54.7%). 
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3.3. Detection of any type of bipolar disorder (BD type I, BD type II or BD NOS) 
3.3.1. Comparison of the BSDS, HCL-32 and MDQ for the detection of bipolar disorder in 
the mental health care setting 
The studies reported different optimal cut-off scores for each of the screening 
instruments (see Supplementary Table S4). Overall, 44 studies (5,021 cases; 17,451 
participants) were performed in mental health services (Figure 2). Table 1 summarizes the 
sensitivities and specificities for the BSDS, MDQ and HCL-32 at specific cut-offs for which 
data were available for a separate meta-analysis of each instrument at a common cut-off. At 
the developer recommended cut-offs of 14, 13, and 7 for the HCL-32, BSDS and MDQ 
respectively, the summary sensitivities were 81% (95% CI 77-85%), 69% (95% CI 63-74%) 
and 66% (95% CI 57-73%); the corresponding summary specificities were 67% (95% CI 47-
82%), 79% (95% CI 72-84%) and 86% (95% CI 74-93%). 
<Insert Table 1 around here> 
<Insert Fig. 2. around here> 
Using all available studies in an indirect comparison (i.e. unrestricted to head-to-
head studies), we compared the test performance of the MDQ (30 studies), the BSDS (8 
studies) and the HCL-32 (17 studies). The shape of the SROC curves significantly differed 
(p=0.002) as well as the accuracy of the screening instruments (p=0.029). Because the shape 
of the SROC curve for each instrument was different and asymmetric, this implies that the 
accuracy of each instrument varies with cut-off. Figure 3 presents the SROC curves for the 
three instruments. The BSDS curve is consistently above the MDQ curve in the region 
containing most of the observed data. The HCL-32 curve is above the MDQ and BSDS 
curve at higher values of specificity, but the curve then crosses both the MDQ and the BSDS 
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curves and accuracy is lower at lower values of specificity.  This is also evident in 
Supplementary Table S5, which shows the sensitivities estimated from the curves at 
quartiles of the observed specificities in included studies. Using quartiles of the observed 
prevalence from the included studies, the table also shows the clinical implications of using 
each of the instruments in a hypothetical cohort of 100 patients. For example, out of a cohort 
of 100 patients with a bipolar disorder prevalence of 18%, and assuming a specificity of 
77%, the sensitivities of MDQ, HCL-32 and BSDS of 70%, 78% and 78% would miss 4, 4, 
and 5 cases respectively, while 19 of those without bipolar disorder would be false positives.  
In direct comparisons, three studies compared the BSDS (469 cases; 622 patients) to 
the MDQ (469 cases; 613 patients). Cut-offs differed between studies for the BSDS, and the 
direction of the differences in sensitivity and specificity were inconsistent. Two of the 
studies reported higher sensitivity and contrasting specificity for the BSDS (at cut-offs 11 
and 13) compared to the MDQ at a cut-off of 5; the third study reported lower sensitivity 
and higher specificity at a cut-off of 14 for the BSDS and a cut-off of 5 for the MDQ. Eight 
studies (448 cases; 1572 patients) directly compared MDQ and HCL-32 (Supplementary 
Figure S3). Despite differences in cut-offs, the results from the eight studies were consistent 
with the HCL-32 showing higher sensitivity and lower specificity than the MDQ. However, 
the curves for the two instruments lie close together and there was no evidence of a 
difference in accuracy (p=0.21). 
3.3.2. Comparison of accuracies of the BSDS, HCL-32 and MDQ in the primary care or 
general population   
 Five studies (240 BD cases; 3,321 participants) evaluated the BSDS (one study), the 
HCL-32 (one study) and the MDQ (four studies) in the primary care setting or general 
population (See supplementary Figure S2 that follows the online version of this article). One 
study directly compared the BSDS to the HCL-32 for the detection of bipolar depression in a 
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primary care sample with depression (29 cases; 576 patients) (Smith et al., 2011). This study 
reported a higher sensitivity and lower specificity for the BSDS at a cutoff of 12 compared 
to the HCL-32 at a cutoff of 18 (Supplementary Figure S2). A meta-analysis comparing the 
three instruments in these settings was not possible due to limited data. Four studies (all with 
an optimum cutoff of 7) investigated the accuracy of the MDQ in the general population or 
primary care setting (182 cases; 2,169 patients/participants). Supplementary Figure S3 
depicts the SROC curve of these four studies. Summary sensitivity and specificity (95% CI) 
were 43.0% (11 to 81%) and 95% (45 to 100%) respectively.  
3.3.3. Detection of Bipolar Disorder type II 
Seventeen studies evaluated the BSDS (3 studies; 59 cases; 392 patients), HCL-32 (5 
studies; 518 cases; 2,430 patients) and MDQ (11 studies; 395 cases; 2,774 patients) for 
detection of BD type II (Figure 4). Two studies were comparative: one compared the HCL-
32 and MDQ, and the other compared the BSDS and MDQ in the same population. All 
seventeen studies were performed in a mental health care setting. 
<Insert Fig. 4. around here> 
We compared the test performance of the BSDS, HCL-32 and MDQ. Figure 5 
presents the SROC curves for the three instruments. The BSDS was not significantly more 
accurate than the MDQ with an RDOR (95% CI) of 1.7 (0.8 to 3.8, p=0.19). However, there 
was evidence that the accuracy of the HCL-32 was superior to that of the MDQ with an 
RDOR of 2.0 (1.1 to 3.4, p=0.018). Supplementary Table S6 shows the sensitivities 
estimated from the curves at the median specificity obtained from the included studies. For 
example, given a cohort of 100 patients with a 15% prevalence of BD type II and a fixed 
specificity of 69%, the MDQ, HCL-32 and BSDS (with sensitivities of 68%, 81% and 78%, 
respectively) would miss 5, 3 and 3 cases respectively, while 26 of those without type II BD 
would be false positives. 
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<Insert Fig. 5. around here> 
3.3.4. Detection of Bipolar Disorder Not Otherwise Specified 
 Two studies (30 cases; 264 patients) reported the diagnostic accuracy of the MDQ 
for detection of BD NOS (see Supplementary Figure S4). Both studies used a cut-off of 7 
and were conducted in a mental health setting.(de Sousa Gurgel et al., 2012; Kim et al., 
2008) The sensitivities were 29% (10-56%) (Kim et al., 2008) and 69% (39-91%) (de Sousa 
Gurgel et al., 2012), and the corresponding specificities were 77% (67-85%) and 80% (72-
86%).  
 
3.4. Assessment of heterogeneity 
 The results of investigations of heterogeneity are summarized in Supplementary 
Table S7 for the three instruments in a mental health care setting. Because few studies 
evaluated the BSDS, we were unable to perform meta-regression analyses to assess 
heterogeneity in the diagnostic accuracy of this instrument.  
For each instrument, we examined the distribution of the percentage of BD cases that 
were BD-II/NOS. The median percentage (interquartile range) for the BSDS (7 studies), 
MDQ (26 studies) and HCL-32 (15 studies) were 55% (32%, 65%), 53% (29%, 62%) and 
54% (36%, 71%) respectively. For the HCL-32, there was no evidence of a difference in 
diagnostic accuracy between studies with a percentage of BD-II/NOS above or below the 
median percentage (p=0.34). Conversely, for the MDQ, there was strong evidence (p<0.001) 
of a difference in diagnostic accuracy between the two groups of studies - studies with a 
percentage of BD-II/NOS above the median showed lower accuracy compared to studies 
below the median with an RDOR (95% CI) of 0.29 (0.15 to 0.59). 
For both the MDQ and HCL-32, there was no evidence of a difference in diagnostic 
accuracy between Asian and non-Asian studies with p= 0.13 and p=0.16, respectively. For 
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the two QUADAS-2 (Whiting et al., 2011) signaling questions, we grouped ‘no’ and 
‘unclear’ responses as one subgroup because our interest was in how the ‘yes’ subgroup 
(indicating low risk of bias) would compare to the ‘no’ or ‘unclear’ subgroups (indicating 
high or unclear risk of bias). For the MDQ, there was evidence to suggest a difference in 
accuracy between studies that enrolled a consecutive or random sample of patients compared 
to studies that did not or were unclear (p=0.03). However, there was no evidence of a 
difference in the accuracy of the HCL-32 (p=0.11). For the MDQ and HCL-32, there was no 
evidence of a difference in accuracy between studies that used a case control design and 
those that did not or were unclear, with p=0.31 and p=0.29 respectively. 
4. Discussion 
 In this meta-analysis, we determined the accuracy properties of the BSDS, HCL-32 
and MDQ for the screening of bipolar spectrum disorders in psychiatric settings. However, 
the diagnostic properties of each instrument varies with cut-offs.  At a cut-off of 7 the 
specificity of the MDQ seemed higher than that of the HCL-32 at a cut-off of 14, while the 
sensitivity of the HCL-32 was higher. This finding was further supported by studies that 
compared both instruments in the same population, even though cut-offs differed between 
studies.  
For the detection of type II BD, the HCL-32 was significantly more accurate than the 
MDQ. Differences in the characteristics of the instruments could explain these findings. The 
MDQ includes a series of questions derived from the DSM-IV criteria for a manic episode 
(Hirschfeld et al., 2000). Since its development, the MDQ has been validated in psychiatric 
settings across a multitude of cultures worldwide. Some investigators raised initial concerns 
that the psychometric properties of the MDQ would be less satisfactory for the detection of 
type II BD (Benazzi, 2003; Mago, 2001). Subsequently, other reports indicated that the 
MDQ had lower accuracy for the detection of more subtle BD cases (for example, type II 
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BD) (Hardoy et al., 2005; Weber Rouget et al., 2005). Hypomania presents in certain 
circumstances a ‘bright’ side specifically in patients who are more elated/active and less 
irritable/risk-taking (Brand et al., 2011; Gamma et al., 2008). Hypomanic individuals on the 
‘bright side’ may rate themselves as more stress-tolerant and self-efficacious (Brand et al., 
2011). Therefore, hypomanic episodes are prone to significant recall bias because a 
significant proportion of individuals may not perceive themselves as ‘abnormal’ when 
experiencing hypomanic symptoms and/or episodes. This may explain why the MDQ, which 
exclusively evaluates self-reported (hypo) manic symptoms is less accurate than the HCL-32 
for detection of type II BD. As a result of this perceived limitation of the MDQ, the HCL-32 
(Angst et al., 2005) and the BSDS (Ghaemi et al., 2005) were developed to improve the 
detection of less exuberant bipolar spectrum disorders (e.g. type II and NOS). Developers of 
the HCL-32 attempted to develop an instrument to screen for bipolar spectrum disorders 
among patients in current depressive episodes through priming the respondent to the cyclical 
nature of BD and including more (hypo) manic manifestations (Angst et al., 2005), while the 
BSDS describes clinical manifestations of BD (including depressive symptoms) and 
emphasizes mood swings.  
   We identified significant sources of heterogeneity in our meta-analyses. First, the 
percentage of type II/NOS BD cases included in each study appeared to affect estimates of 
the performance of the MDQ. Conversely, the proportion of type II/NOS BD cases did not 
affect the diagnostic accuracy of the HCL-32. This analysis provide further support that the 
HCL-32 is more accurate than the MDQ for the detection of ‘softer’(Angst and Marneros, 
2001) BD cases. Second, categorization of studies into ‘Asian’ versus ‘non-Asian’ did not 
explain heterogeneity in study results for the HCL-32 or the MDQ. We performed these 
analyses because previous reports found lower sensitivity for the MDQ in Asian samples 
(Chung et al., 2008; Hu et al., 2012; Kim et al., 2008). Specifically, the impairment question 
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of the MDQ seemed to explain its lower sensitivity in Asian cultures as an alternative 
scoring procedure eliminating this MDQ criteria restored the sensitivity of the instrument 
(Chung et al., 2008; Kim et al., 2008). We did not find evidence to support lower accuracy 
of the MDQ in Asian populations. Third, we found that a ‘No’ or ‘Unclear’ answer to the 
QUADAS-2 signaling question ‘Was a consecutive or random sample of patients enrolled?’ 
had a significant effect on test accuracy. Taking into account that several studies were 
performed in tertiary mental health care centers, selection of non-random/non-consecutive 
samples (and consequently prior knowledge of case status) may over-estimate the accuracy 
properties of a screening tool. Although case-control studies are prone to bias, the 
QUADAS-2 signaling question ‘Was a case-control design avoided?’ did not affect the 
accuracy of the MDQ or the BSDS. However, these results should be interpreted with 
caution as relatively few studies were rated as either a ‘No’ or ‘Unclear’ response to this 
question.  
 A recent systematic review indicated that BD may be a prevalent and under-
recognized mental disorder in primary care (Cerimele et al., 2014). The authors found a 
lower prevalence for BD when structured diagnostic interviews were used (range 0.5 to 
4.3%) compared to a screening instrument (7.6 to 9.8%). This finding highlights the 
possibility that a positive screen for BD may include a high number of false positive cases. 
Our meta-analysis indicated that the MDQ has a lower sensitivity for the detection of BD in 
primary care or general population settings compared to psychiatric settings. However, the 
instrument retained a high specificity in these settings. However, both sensitivity and 
specificity were subject to substantial uncertainty due to the small number of studies and 
between-study variation in estimates of test performance. A single study compared the 
BSDS to the HCL-32 for the detection of BD among primary care patients with depression 
(Smith et al., 2011). Accordingly, in this study both instruments had low positive predictive 
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values (0.3 and 0.5, respectively). Evidence thus far indicates that these instruments may 
have lower sensitivity for the detection of BD in these settings compared to mental health 
centers. Several complex factors may contribute to this finding, notably prior-knowledge of 
disease status in mood disorder clinics. 
4.1. Strengths and Limitations 
 The main strengths of this review include the use of internationally recommended 
methods for study identification and selection, quality assessment and meta-analysis. 
Furthermore, this meta-analysis included a large number of studies and participants. 
Nevertheless, there were limitations. First, the comparative accuracy of the three instruments 
was determined mainly through indirect comparisons. Indirect comparisons are prone to 
confounding due to differences in study and population characteristics (Takwoingi et al., 
2013). However, for the detection of any type of bipolar disorder, we also performed a direct 
comparison of the HCL-32 and MDQ, and results were consistent with the indirect 
comparison. Second, several different cut-offs were used for each instrument and we used 
the optimal cut-off that was reported in each study for our analyses. Selective reporting of 
optimal cut-offs can introduce bias if the selection is data driven but the bias is minimized in 
large studies (Leeflang et al., 2008). Because the median sample size in our review was 164 
(interquartile range 122 to 363), we expect any bias to be minimal even if some of the 
included studies used a data driven approach to select the optimum cut-off. Furthermore, we 
compared the accuracy of the three instruments across the range of cut-offs by performing 
HSROC analyses. Third, the methodological quality of many of the included studies was 
limited. We investigated the effect of two relevant items of the QUADAS-2 tool on test 
performance. Fourth, included articles used the DSM-IV criteria as the reference standard. 
The DSM-5 introduced important changes in the taxonomy of mood disorders. Thus, the 
summary accuracy properties obtained in this review may be different considering DSM-5 
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criteria as reference standard. Finally, the DSM-5 field trials revealed that the inter-rater 
reliabilities for type I BD (kappa=0.56) and especially for type II BD (kappa=0.40) are not 
optimal (Freedman et al., 2013). Therefore, the accuracy of screening instruments should be 
interpreted considering intrinsic limitations of the ‘gold standard’ (i.e., the reliability of a 
DSM-based structured psychiatric interview).  
4.2. Clinical Implications 
 This review indicates that the accuracy of the BSDS, HCL-32 and MDQ are cut-off 
dependent. The instruments should not be considered case-finding tools , because  a 
substantial proportion of patients who screen positive for BD do not actually have the 
disorder.(Zimmerman, 2014) Therefore, a confirmatory diagnostic interview should follow a 
positive screen. Furthermore, a higher frequency of BD II/NOS amongst BD cases has a 
negative impact on the accuracy of the MDQ. For the detection of type II BD, the HCL-32 is 
superior to the MDQ. A meta-analysis of test accuracy provides a relevant first-step in test 
evaluation but other factors should be carefully considered.(Leeflang et al., 2013) For 
example, cost-effectiveness analyses assessing the cost implications of false positives 
associated with the use of BD screening measures is important. However, it should be noted 
that the cost-effectiveness of case identification is complex to model and requires a number 
of assumptions concerning probabilities assigned in the BD treatment care pathway, and 
explicit values of treatment outcomes.(Menzin et al., 2009; Valenstein et al., 2001) A 
previous cost effectiveness analysis indicated that a one-time administration of the MDQ in 
primary care patients with a major depressive episode would result in significant reductions 
in 5-year costs to managed-care plans.(Menzin et al., 2009) Finally, well-designed 
randomized controlled trials (RCT) of BD screening will provide evidence related to patient 
outcomes. To our knowledge, no RCT has evaluated the effectiveness of BD screening on 
patient outcomes. Finally, a relevant clinical implication for improving the screening of 
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bipolar disorder among patients with a major depressive episode would be a better accuracy 
in treatment prescription as antidepressant monotherapy may be associated with a 
heightened risk of hospitalization due to mania(Pacchiarotti et al., 2013) and is clearly not 
recommended for type I BD patients.(Vieta, 2014; Viktorin et al., 2014) Therefore, a better 
discrimination between unipolar and bipolar I depression would potentially result in 
improved outcomes and a reduced risk of iatrogeny.  
4.3. Implications for Research 
 Screening tools for BD have been used in large-scale epidemiological surveys as 
proxies to estimate the prevalence of BD in primary care(Cerimele et al., 2014) and in the 
general population.(Hirschfeld et al., 2003) This review provides evidence that researchers 
should clearly differentiate a positive screen for BD due to the number of false positives 
associated with BD screening. There were few studies of the BSDS in a mental health 
setting compared to studies of the HCL-32 and the MDQ. The limited evidence from 
primary care and general population settings indicate that the sensitivity of the MDQ is 
lower in these settings than in mental health center settings. Future studies should investigate 
the diagnostic properties of the three screening instruments in primary care.  
5. Conclusions  
 Screening instruments for BD have elevated specificities indicating that these scales 
would effectively screen out a large proportion of true negatives. However, a positive screen 
should be confirmed by a clinical diagnostic evaluation for BD. The accuracy properties of 
the MDQ and HCL-32 are supported by a larger evidence base than those of the BSDS. The 
HCL-32 is more accurate for the detection of type II BD than the MDQ in mental health care 
settings.  
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Fig. 1. PRISMA flowchart of Study Selection 
Fig. 2. Forest plot of BSDS, HCL-32 and MDQ for detection of bipolar disorder in mental 
health settings. The plot shows study specific estimates of sensitivity and specificity (with 
95% confidence intervals) at a specific cut-off. The studies are ordered according to cut-off 
and % BDII/NOS. Where % BDII/NOS is blank, the information was not reported by the 
study. % BDII/NOS = percentage of bipolar cases that were bipolar disorder type II or not 
otherwise specified; FN = false negative; FP = false positive; TN = true negative; TP = true 
positive. 
Fig. 3. Summary ROC plots of the BSDS, HCL-32 and MDQ for detection of bipolar 
disorder in mental health center setting. For each test, each symbol represents the pair of 
sensitivity and specificity from a study. The size of the symbols is scaled according to the 
sample size of the study. Plotted curves are restricted to the range of specificities for each 
instrument. 
Fig. 4. Forest plot of HCL-32 and MDQ for detection of bipolar disorder type II. The plot 
shows study specific estimates of sensitivity and specificity (with 95% confidence intervals) 
at a specific cut-off. All studies were performed in a mental health setting. The studies are 
ordered according to cut-off and study name.FN=false negative; FP=false positive; TN=true 
negative; TP=true positive. 
Fig. 5. Summary ROC plot of the BSDS, HCL-32 and MDQ for detection of bipolar 
disorder type II in mental health center setting. For each test, each symbol represents the pair 
of sensitivity and specificity from a study. The size of the symbols is scaled according to the 
sample size of the study. Plotted curves are restricted to the range of specificity for each 
instrument. 
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Table 1. Summary diagnostic characteristics of BSDS, HCL-32 and MDQ for detection of any type 
of bipolar disorder in mental health center and primary care or general population settings, 
according to test cut-off. 
Instrument Cut-off N Cases Patients Sensitivity (95% CI) 
Specificity 
(95% CI) 
Mental health setting 
BSDS 13 3 113 559 69% (63% to 74%) 86% (74% to 93%) 
HCL-32 14 9 1,845 4,807 81% (77% to 85%) 67% (47% to 82%) 
MDQ 6 3 165 447 81% (73% to 88%) 85% (79% to 89%) 
 
7 19 969 3,220 66% (57% to 73%) 79% (72% to 84%) 
Primary care or general population setting 
MDQ 7 4 182 2,169 43% (11% to 81%) 95% (45% to 100%) 
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